D M Zapzalka1, J B Redmon, J L Pryor. 1. Department of Urologic Surgery, University of Minnesota, Fairview-University Medical Center, Minneapolis, Minnesota, USA.
Abstract
BACKGROUND: The authors surveyed the current knowledge, opinions, and clinical practices of oncologists regarding pretherapy cryopreservation of semen from male cancer patients since the introduction of intracytoplasmic sperm injection (ICSI). METHODS: A survey was sent to all members of the American Society of Clinical Oncology in Minnesota. RESULTS: Forty-six of 165 oncologists (28%) responded. Factors considered important in how strongly to recommend cryopreservation were patient age at the time of diagnosis (94%), type of treatment (83%), type of cancer (65%), urgency to initiate treatment (63%), and preexisting infertility (57%). Oncologists perceived patients to be significantly more concerned about cryopreservation than they were themselves during pretherapy counseling (P = 0.0005). Oncologists estimated that 27% of their patients chose to cryopreserve sperm. However, only 26% of the oncologists knew about ICSI. The cancers perceived to warrant cryopreservation the most were lymphomas, leukemias, and testicular carcinomas. The treatment modalities perceived to warrant cryopreservation the most were distributed among various chemotherapy and radiation regimens. A majority of respondents to the survey knew where patients could go to cryopreserve sperm (89%), but less than half of the respondents gave accurate information about the cost. CONCLUSIONS: Most of the oncologists surveyed were unaware of recent advances in reproductive technology in which only a few sperm are needed for successful in vitro fertilization with ICSI. This lack of awareness may be contributing to underutilization of sperm cryopreservation by male cancer patients. Currently, all male cancer patients of reproductive age who will have treatment that may affect testicular function and who may desire children in the future should cryopreserve sperm before the initiation of therapy. Copyright 1999 American Cancer Society.
BACKGROUND: The authors surveyed the current knowledge, opinions, and clinical practices of oncologists regarding pretherapy cryopreservation of semen from male cancerpatients since the introduction of intracytoplasmic sperm injection (ICSI). METHODS: A survey was sent to all members of the American Society of Clinical Oncology in Minnesota. RESULTS: Forty-six of 165 oncologists (28%) responded. Factors considered important in how strongly to recommend cryopreservation were patient age at the time of diagnosis (94%), type of treatment (83%), type of cancer (65%), urgency to initiate treatment (63%), and preexisting infertility (57%). Oncologists perceived patients to be significantly more concerned about cryopreservation than they were themselves during pretherapy counseling (P = 0.0005). Oncologists estimated that 27% of their patients chose to cryopreserve sperm. However, only 26% of the oncologists knew about ICSI. The cancers perceived to warrant cryopreservation the most were lymphomas, leukemias, and testicular carcinomas. The treatment modalities perceived to warrant cryopreservation the most were distributed among various chemotherapy and radiation regimens. A majority of respondents to the survey knew where patients could go to cryopreserve sperm (89%), but less than half of the respondents gave accurate information about the cost. CONCLUSIONS: Most of the oncologists surveyed were unaware of recent advances in reproductive technology in which only a few sperm are needed for successful in vitro fertilization with ICSI. This lack of awareness may be contributing to underutilization of sperm cryopreservation by male cancerpatients. Currently, all male cancerpatients of reproductive age who will have treatment that may affect testicular function and who may desire children in the future should cryopreserve sperm before the initiation of therapy. Copyright 1999 American Cancer Society.
Authors: Danny M Rabah; Iman H Wahdan; Abdelmalek Merdawy; Bassem Abourafe; Mostafa A Arafa Journal: J Cancer Surviv Date: 2010-07-23 Impact factor: 4.442
Authors: Tobias S Köhler; Laxmi A Kondapalli; Amul Shah; Sarah Chan; Teresa K Woodruff; Robert E Brannigan Journal: J Assist Reprod Genet Date: 2010-11-26 Impact factor: 3.412
Authors: Maciej Murawski; Tomasz Schwarz; Joanna Grygier; Krzysztof Patkowski; Zdzisław Oszczęda; Igor Jelkin; Anna Kosiek; Tomasz M Gruszecki; Anna Szymanowska; Tomasz Skrzypek; Dorota A Zieba; Pawel M Bartlewski Journal: Exp Biol Med (Maywood) Date: 2014-12-08
Authors: Ercole Brusamolino; Andrea Bacigalupo; Giovanni Barosi; Giampaolo Biti; Paolo G Gobbi; Alessandro Levis; Monia Marchetti; Armando Santoro; Pier Luigi Zinzani; Sante Tura Journal: Haematologica Date: 2009-03-10 Impact factor: 9.941